Layperson’s Summary Clause Samples
Layperson’s Summary. Acute myeloid leukemia (AML) is a cancer that begins in bone marrow and affects cells intended to mature into different types of blood cells. Research shows that interaction between the AXL receptor and its ligand (GAS6) leads to more severe and invasive cases of AML. To address the need for more effective therapies, Ruga has developed Ruga-S6, an engineered decoy receptor that binds to GAS6 and inhibits its binding to the actual AXL receptor. It has also developed a proprietary blood-based companion diagnostic that could potentially identify ideal patient candidates for Ruga-S6 treatment. In both laboratory and animal experiments, inhibition of the AXL-GAS6 interaction stops the progression of AML. Other treatments in development have toxicity and low response rates with increased likelihood of developing resistance; critical issues that are addressed with Ruga’s therapeutic approach. Ruga-S6 has the opportunity to seek FDA Orphan drug and Breakthrough status. By advancing Ruga-S6 through preclinical and clinical testing, Ruga may provide a more effective therapeutic option for AML and other aggressive cancers, including ovarian, endometrial, breast, renal and pancreatic. The development of Ruga-S6 aligns with CPRIT’s focus on rare and pediatric cancers and those of significant unmet clinical need. If funded, Ruga will fully relocate to Texas, where it will continue the development of Ruga-S6 in partnership with Texas-based institutions, including the Texas Medical Center. Timelines: EDITED project_timeline.pdf Goal 1 ADDED Year 1 Support growth of the State’s biopharmaceutical industry by establishing Texas as the corporate headquarters for the Company and specifically, the Texas Medical Center (TMC) as the hub for all advanced preclinical and clinical development activities for the Company’s novel fusion protein (Ruga-S6). Contribute to the local and State economies by relocating key personnel and creating new high-quality, professional jobs that are required to fully support the company’s performance of the oncology project utilizing the Company’s fusion protein to serve as an AXL decoy (the “CPRIT Project”). Further, develop strategic partnerships and initiate activities with Texas-based subcontractors and consultants that can provide the expertise, services, and infrastructure needed to accomplish the preclinical and clinical development of the CPRIT Project.
Layperson’s Summary. In 2015, there were approximately 27,000 new cases of multiple myeloma diagnosed in the US making it the second most prevalent blood cancer. The five-year survival rate for multiple myeloma is 45% and the median survival is approximately 4 years. CD38 is a protein expressed on the surface of myeloma cells. Recently, daratumumab, an antibody that specifically targets CD38, was approved for the treatment of patients with multiple myeloma. Daratumumab works primarily by binding myeloma cells and recruiting an immune response to them. Most patients’ immune system will ultimately stop responding to daratumumab allowing the disease to progress. Molecular Templates, a venture-backed biopharmaceutical company in Georgetown, TX, has developed a novel multiple myeloma drug that targets CD38 but works in a different way from daratumumab. MT-4019ND is a fusion of an antibody fragment that binds CD38 with a highly toxic bacterial protein. MT-4019ND binds CD38 on the surface of myeloma cells but instead of recruiting an immune response, it directly kills the myeloma cell through its toxin component. MT-4019ND has shown a potent ability to kill myeloma cell lines in the laboratory and in animal models of myeloma. Molecular Templates has a similar compound in the clinic for lymphoma that appears safe and effective in patients. Molecular Templates seeks $15.3M in CPRIT financing to move MT-4019ND through clinical studies in patients with refractory multiple myeloma. Timelines:project_timeline.pdf O pen MT-4019 IND Upon funding, Molecular Templates would initiate IND-required studies. These studies would include two GLP repeat dose toxicity studies in the appropriate rodent and ADDED non-human primate species, non-GLP studies in rodent and non-human primate, a GLP TCR assay, all required assay development and validation, and establishment of the PK profile for MT-4019ND. In parallel, process development and expression of MT-4019ND for GMP materials will commence upon funding. Molecular Templates has considerable experience in conducting IND-enabling studies and in the manufacture of GMP material for its scFv-SLTA fusions. Objective 1: Satisfy FDA requirements for successful IND application Use toxicology studies to establish a starting dose in humans that is expected to be safe and may potentially provide benefit Objective 3: Create sufficient GMP material to cover drug needs in Phase I Initiation of Phase I First-in-Man Clinical Trial in Rel...